NCT06720350View on ClinicalTrials.gov

Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

October 15, 2026

Study Completion Date

December 15, 2026

Conditions
Osteoporosis in Post-menopausal Women
Interventions
DRUG

Romosozumab and Denosumab Combination Therapy

Romosozumab 210mg per month and denosumab 60mg per 6 months will be applied

DRUG

Romosozumab Prefilled Syringe [Evenity]

Romosozumab 210mg subcutaneously per month

DRUG

Denosumab (Prolia)

Denosumab 60 mg subcutaneously per 6 months

Trial Locations (1)

Unknown

Marmara University, Istanbul

Sponsors

Lead Sponsor

Marmara University
All Listed Sponsors
lead

Marmara University

OTHER